Market Cap 3.70B
Revenue (ttm) 642.82M
Net Income (ttm) -43.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6.77%
Debt to Equity Ratio 0.00
Volume 2,960,400
Avg Vol 2,834,380
Day's Range N/A - N/A
Shares Out 126.96M
Stochastic %K 21%
Beta 2.12
Analysts Sell
Price Target $25.38

Company Profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and singl...

Industry: Health Information Services
Sector: Healthcare
Phone: 925 401 7300
Address:
6230 Stoneridge Mall Road, Pleasanton, United States
MorganHoratio
MorganHoratio Jun. 9 at 11:32 PM
During this market downturn, please pay attention to the following stocks: Health: $ABCL $VKTX $HIMS $TXG $CRSP An exceptional high-alpha radar for the healthcare sector! This local macro consolidation is providing a premium entry zone for true clinical disrupters and digital health compounders. The fundamental catalysts driving this group are deeply institutional. HIMS is a standout hyper-growth monster, surging over 6% into the $28 node backed by relentless expansion in its customized weight-loss workstreams and explosive net income inflections. VKTX represents an elite macro-accumulation play ahead of its critical oral obesity data milestones, while CRSP and TXG (10x Genomics) lock in structural, irreplaceable moats across gene-editing and spatial biology instrumentation. As capital rotates into high-conviction health tech, are you compounding shares in the immediate cash-flow powerhouse HIMS, or front-running the technical floors on VKTX and CRSP?
1 · Reply
WalterWhite13
WalterWhite13 Jun. 9 at 3:52 PM
0 · Reply
DiamondHandsDO
DiamondHandsDO Jun. 8 at 8:04 PM
$TXG load up!
0 · Reply
Estimize
Estimize Jun. 8 at 11:00 AM
Wall St is expecting -0.23 EPS for $TXG Q2 [Reporting 08/06 AMC] http://www.estimize.com/intro/txg?chart=historical&metric_name=eps&utm_con
0 · Reply
jacobmintz
jacobmintz Jun. 5 at 12:08 AM
Cabot Options Trader Call Buying Activity: $TXG $TEM $NBIS $QCOM $NOK
1 · Reply
WOLFSTREET
WOLFSTREET Jun. 4 at 10:28 PM
$TXG WHAT A DAY ON A GREAT STOCK! Too soon for CC to be doing this?
0 · Reply
WallStJesus
WallStJesus Jun. 4 at 2:37 PM
0 · Reply
WallStJesus
WallStJesus Jun. 4 at 2:34 PM
$TXG REPEAT BULL SWEEPER DETECTED
0 · Reply
Avocado_smash
Avocado_smash Jun. 4 at 4:33 AM
$TXG Bullish, Structure and Trend look like will go even higher>
0 · Reply
john_clout_67
john_clout_67 Jun. 4 at 3:37 AM
$TXG very early imo
0 · Reply
Latest News on TXG
10x Genomics acquires Proteintech Genomics

2026-06-09T13:11:53.000Z - 2 days ago

10x Genomics acquires Proteintech Genomics


10x Genomics price target raised to $20 from $17 at JPMorgan

2026-05-12T12:26:29.000Z - 4 weeks ago

10x Genomics price target raised to $20 from $17 at JPMorgan


10x Genomics reports Q1 EPS (10c), consensus (6c)

2026-05-07T21:30:11.000Z - 5 weeks ago

10x Genomics reports Q1 EPS (10c), consensus (6c)


10x Genomics Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 weeks ago

10x Genomics Earnings Call Transcript: Q1 2026


10x Genomics Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 weeks ago

10x Genomics Earnings release: Q1 2026


10x Genomics Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 weeks ago

10x Genomics Quarterly report: Q1 2026


10x Genomics Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 5 weeks ago

10x Genomics Reports First Quarter 2026 Financial Results


10x Genomics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 6 weeks ago

10x Genomics Proxy statement: Proxy filing


10x Genomics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 6 weeks ago

10x Genomics Proxy statement: Proxy filing


10x Genomics price target raised to $32 from $22 at Canaccord

2026-04-20T14:03:59.000Z - 7 weeks ago

10x Genomics price target raised to $32 from $22 at Canaccord


10x Genomics price target raised to $30 from $21 at BofA

2026-04-20T13:43:54.000Z - 7 weeks ago

10x Genomics price target raised to $30 from $21 at BofA


10x Genomics Slides: Corporate presentation

Apr 17, 2026, 7:00 AM EDT - 7 weeks ago

10x Genomics Slides: Corporate presentation


10x Genomics price target raised to $30 from $22 at Barclays

2026-04-14T10:50:31.000Z - 2 months ago

10x Genomics price target raised to $30 from $22 at Barclays


10x Genomics price target raised to $24 from $18 at Citi

2026-04-07T10:15:11.000Z - 2 months ago

10x Genomics price target raised to $24 from $18 at Citi


10x Genomics falls -13.8%

2026-03-16T16:06:47.000Z - 3 months ago

10x Genomics falls -13.8%


10x Genomics Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 4 months ago

10x Genomics Earnings Call Transcript: Q4 2025


10x Genomics Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 4 months ago

10x Genomics Annual report: Q4 2025


10x Genomics Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 4 months ago

10x Genomics Earnings release: Q4 2025


10x Genomics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 5 months ago

10x Genomics Slides: 44th Annual J.P. Morgan Healthcare Conference


10x Genomics Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 11:20 AM EST - 7 months ago

10x Genomics Transcript: Wolfe Research Healthcare Conference 2025


10x Genomics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

10x Genomics Earnings Call Transcript: Q3 2025


10x Genomics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

10x Genomics Quarterly report: Q3 2025


10x Genomics Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

10x Genomics Earnings release: Q3 2025


10x Genomics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

10x Genomics Reports Third Quarter 2025 Financial Results


10x Genomics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

10x Genomics Earnings Call Transcript: Q2 2025


10x Genomics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

10x Genomics Quarterly report: Q2 2025


10x Genomics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

10x Genomics Earnings release: Q2 2025


10x Genomics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 11 months ago

10x Genomics Reports Second Quarter 2025 Financial Results


10x Genomics to Acquire Scale Biosciences

Aug 7, 2025, 4:04 PM EDT - 11 months ago

10x Genomics to Acquire Scale Biosciences


10x Genomics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

10x Genomics Earnings Call Transcript: Q1 2025


10x Genomics Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

10x Genomics Quarterly report: Q1 2025


10x Genomics Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

10x Genomics Earnings release: Q1 2025


10x Genomics Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

10x Genomics Reports First Quarter 2025 Financial Results


10x Genomics Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

10x Genomics Proxy statement: Proxy Filing


10x Genomics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

10x Genomics Proxy statement: Proxy Filing


10x Genomics Earnings Call Transcript: Q4 2024

Feb 12, 2025, 4:30 PM EST - 1 year ago

10x Genomics Earnings Call Transcript: Q4 2024


10x Genomics Annual report: Q4 2024

Feb 12, 2025, 4:30 PM EST - 1 year ago

10x Genomics Annual report: Q4 2024


10x Genomics Earnings release: Q4 2024

Feb 12, 2025, 4:30 PM EST - 1 year ago

10x Genomics Earnings release: Q4 2024


10x Genomics Slides: FY 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

10x Genomics Slides: FY 2025


10x Genomics Earnings Call Transcript: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

10x Genomics Earnings Call Transcript: Q3 2024


10x Genomics Quarterly report: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

10x Genomics Quarterly report: Q3 2024


10x Genomics Earnings release: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

10x Genomics Earnings release: Q3 2024


10x Genomics Slides: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

10x Genomics Slides: Q3 2024


10x Genomics Reports Third Quarter 2024 Financial Results

Oct 29, 2024, 4:05 PM EDT - 1 year ago

10x Genomics Reports Third Quarter 2024 Financial Results


MorganHoratio
MorganHoratio Jun. 9 at 11:32 PM
During this market downturn, please pay attention to the following stocks: Health: $ABCL $VKTX $HIMS $TXG $CRSP An exceptional high-alpha radar for the healthcare sector! This local macro consolidation is providing a premium entry zone for true clinical disrupters and digital health compounders. The fundamental catalysts driving this group are deeply institutional. HIMS is a standout hyper-growth monster, surging over 6% into the $28 node backed by relentless expansion in its customized weight-loss workstreams and explosive net income inflections. VKTX represents an elite macro-accumulation play ahead of its critical oral obesity data milestones, while CRSP and TXG (10x Genomics) lock in structural, irreplaceable moats across gene-editing and spatial biology instrumentation. As capital rotates into high-conviction health tech, are you compounding shares in the immediate cash-flow powerhouse HIMS, or front-running the technical floors on VKTX and CRSP?
1 · Reply
WalterWhite13
WalterWhite13 Jun. 9 at 3:52 PM
0 · Reply
DiamondHandsDO
DiamondHandsDO Jun. 8 at 8:04 PM
$TXG load up!
0 · Reply
Estimize
Estimize Jun. 8 at 11:00 AM
Wall St is expecting -0.23 EPS for $TXG Q2 [Reporting 08/06 AMC] http://www.estimize.com/intro/txg?chart=historical&metric_name=eps&utm_con
0 · Reply
jacobmintz
jacobmintz Jun. 5 at 12:08 AM
Cabot Options Trader Call Buying Activity: $TXG $TEM $NBIS $QCOM $NOK
1 · Reply
WOLFSTREET
WOLFSTREET Jun. 4 at 10:28 PM
$TXG WHAT A DAY ON A GREAT STOCK! Too soon for CC to be doing this?
0 · Reply
WallStJesus
WallStJesus Jun. 4 at 2:37 PM
0 · Reply
WallStJesus
WallStJesus Jun. 4 at 2:34 PM
$TXG REPEAT BULL SWEEPER DETECTED
0 · Reply
Avocado_smash
Avocado_smash Jun. 4 at 4:33 AM
$TXG Bullish, Structure and Trend look like will go even higher>
0 · Reply
john_clout_67
john_clout_67 Jun. 4 at 3:37 AM
$TXG very early imo
0 · Reply
financials_please
financials_please Jun. 1 at 12:14 AM
$TXG So based on how they seem to be going on the smaller side with the CLIA lab (they said they're simply leveraging assets they have lying around), it seems to mainly be a way to generate clinical evidence for diagnostics and snap up mindshare/trust for physicians as a first mover. The revenue never hurts but probably not a huge boost by itself for a while. But I think it will be a huge value add in the long run since it would speed up the development timeline on any clinical diagnostics and also lead to a faster ramp of test orders once its available. Their software legalese also bans use of 10x Cloud data analysis tools for commercial use (someone can't use it for something that they themselves are selling). Between this and the above point, I think the most likely path forward is to (eventually) develop the CDx kits, manufacture/sell them, have customers with existing CLIA labs run them (eg Labcorp), and promote the test and its performance to physicians to drive adoption.
1 · Reply
WOLFSTREET
WOLFSTREET May. 31 at 5:25 PM
$TXG If CC was a car. It would $RACE itself.
0 · Reply
WOLFSTREET
WOLFSTREET May. 31 at 5:23 PM
$TXG I really hate those screen shots, that there is CC9.4, really not that long ago, but the past 18 months have turned CC from a $F mustang into a $RACE Ferarri F80 No matter what it looked like before, just last July, less than 1 year ago. I had the engine, presentation was still in dev and patience was necessary. UP 115% here so far. GAS UP!
0 · Reply
WOLFSTREET
WOLFSTREET May. 31 at 5:18 PM
$TXG DO NOT SAY I AM NOT PAYING MY CC GOOD FORTUNE FORWARD! BEEN DOING IT FOR SOME TIME. So CC9.8 seriously banging enhancements got me fired, up as U can C. "P" was just the latest push higher within the CC arsenal. S2 has joined the party and projecting a step 1 of nearly 50% gains from here, this is significant!!. S1, our autopilot current mode is not shown, I do not think you can handle it, so something I will just have to prove to you later. U know I have to blur, CC is soon going public and IP protection is critical. Just look at all the noobs on you-tube that would kill for just 10% of this platform. You already know this is an industrial strength tool designed just for the average joe (ME). Does not even the playing field, this makes the playing field 100% uneven to my favor. Stay the course and post less nonsense. BEARS SLEEPING HERE 2.
0 · Reply
WalterWhite13
WalterWhite13 May. 28 at 3:21 PM
$TXG $40 incoming!!!!
0 · Reply
Estimize
Estimize May. 25 at 11:06 AM
Wall St is expecting -0.23 EPS for $TXG Q2 [Reporting 08/06 AMC] http://www.estimize.com/intro/txg?chart=historical&metric_name=eps&utm_con
0 · Reply
Avocado_smash
Avocado_smash May. 23 at 8:17 PM
$TXG Structures and Trends strength up>
0 · Reply
ArmLee
ArmLee May. 18 at 9:53 PM
$RXRX $TEM $TXG $CRSP Great companies to benefit in the era of Biology! All 10X opportunities.
0 · Reply
MarketBeat
MarketBeat May. 9 at 6:08 AM
10x Genomics Q1 Earnings Call Highlights $TXG https://www.marketbeat.com/instant-alerts/10x-genomics-q1-earnings-call-highlights-2026-05-09
0 · Reply
financials_please
financials_please May. 8 at 8:42 PM
$TXG Some napkin math from the earnings call and past results when Xenium shipped. Current guidance is for 40 instruments to get placed in H2, heavily biased toward Q4 and maintaining max guidance of 625M (for now). Xenium sold 255 instruments in it's first year. With the demand/backlog they hint at, 200 instruments in 2027 is not unreasonable with ramp up. Assuming 80% utilization for the first 40 instruments that go to core facilities and other high volume customers, pull through for that batch in 2027 should be 64M. 2027 Atera instrument revenue should be 100M. If we assume the 200 instruments are sold in a linearly increasing rate then we can assume an average of 100 instruments consuming for the full year from that batch. Let's assume a lower rate of utilization for this batch to be safe, say 50%, which gives us 100M in revenue. Xenium placements should go down but Chromium revenue is expected to increase so let's call that a wash.
1 · Reply
BudskieMcgee
BudskieMcgee May. 8 at 12:55 AM
$TXG what an earnings report! This thing is a serious sleeper. Once Atera launches and we start getting 4x pull through the revenue will be through the roof.
2 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:09 PM
$TXG Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.10 up 64.29% YoY • Reported revenue of $150.84M down -2.61% YoY • 10x Genomics is maintaining its full year 2026 revenue guidance of $600M to $625M, representing 0% to 4% growth over full year 2025, excluding non-recurring license and royalty revenue.
0 · Reply